Compare FOR & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | DMRA |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2007 | 2020 |
| Metric | FOR | DMRA |
|---|---|---|
| Price | $28.36 | $28.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $32.67 | ★ $43.00 |
| AVG Volume (30 Days) | 151.7K | ★ 841.0K |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $1,662,400,000.00 | N/A |
| Revenue This Year | $0.34 | N/A |
| Revenue Next Year | $7.73 | N/A |
| P/E Ratio | $17.12 | ★ N/A |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $22.81 | $16.50 |
| 52 Week High | $32.06 | $34.89 |
| Indicator | FOR | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 53.60 |
| Support Level | $28.18 | $22.71 |
| Resistance Level | $29.44 | N/A |
| Average True Range (ATR) | 1.03 | 2.72 |
| MACD | -0.40 | -0.19 |
| Stochastic Oscillator | 43.38 | 35.35 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.